Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: Baseline data from the INSTIGATE study

Current Medical Research and Opinion

Volumn 25, Issue 3, 2009, Pages 691-700

  Jones, Stephen ^a   Benroubi, Marian ^b   Castell, Conxa ^c   Goday, Albert ^d   Liebl, Andreas ^e   Timlin, Louise ^f   Nicolay, Claudia ^g   Simpson, Alexander ^f   Tynan, Aodan ^f  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b IASO GENERAL HOSPITAL   (Greece)

^c GENERALITAT DE CATALUNYA   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e Fachklinik Bad Heilbrunn   (Germany)

^f ELI LILLY AND COMPANY   (United States)

^g LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Concomitant diseases; Glycaemic control; Insulin therapy; Oral anti diabetic agents; Type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE CONTROL; DRUG USE; DYSLIPIDEMIA; EUROPE; FEMALE; FRANCE; GERMANY; GLUCOSE BLOOD LEVEL; GREECE; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROANGIOPATHY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OPEN STUDY; PRACTICE GUIDELINE; PREVALENCE; PROSPECTIVE STUDY; SPAIN; UNITED KINGDOM;

EID: 67649321802     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902739669     Document Type: Article

References (26)

1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412 (Pubitemid 30609442)
2. Roper NA, Bilous RW, Kelly WF, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 2001;322:1389-1393 (Pubitemid 32523292)
3. Rathmann W, Giani G. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:2568-2569
4. Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:181-189 (Pubitemid 32048520)
5. Ettaro L, Songer TJ, Zhang P, et al. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 2004;22:149-164 (Pubitemid 38333648)
6. Leahy JL. Impaired beta-cell function with chronic hyperglycemic; 'overworked beta-cell' hypothesis. Diabetes Rev 1996;4:298-319
7. The UK Prospective Diabetes Study Group. UK prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258
8. The UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
9. European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. Diabet Med 1999;16:716-730 (Pubitemid 29459269)
10. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006;29(Suppl. 1):S4-42
11. Wright A, Burden ACF, Paisey RB, et al. Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-336 (Pubitemid 41079631)
12. Liebl A, Breitscheidel L, Nicolay C, et al. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study. Curr Med Res Opin 2008;24:2349-2358
13. The International Diabetes Federation (IDF). The IDF Worldwide Definition of the Metabolic Syndrome 2006. Available at: www.idf.org/home/index.cfm?node= 1429 [Last accessed 16 July 2007]
14. Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006;29:531-537
15. Rubino A, McQuay LJ, Gough SC, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007;24:1412-1418 (Pubitemid 350179434)
16. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: An update. Hypertension 1995;26:869-879
17. Weir MR. Diabetes and hypertension: blood pressure control and consequences. Am J Hypertens 1999;12:170S-8S
18. The UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998;317:703-713
19. Hillier TA, Fosse S, Balkau B, et al. Weight, the metabolic syndrome, and coronary heart disease in Type 2 diabetes: associations among a national French sample of adults with diabetes - The ENTRED Study. Cardiometab Syndr 2006;1:318-325
20. Pischon T, Hu FB, Rexrode KM, et al. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 2008;197:392-399 (Pubitemid 351273261)
21. Hunt KJ, Williams K, Hazuda HP, et al. The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: the San Antonio Heart Study. Ann Epidemiol 2007;17:870-877 (Pubitemid 47588953)
22. Nakar S, Yitzhaki G, Rosenberg R, et al. Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications 2007;21:220-226 (Pubitemid 47002315)
23. The International Diabetes Federation, European Region (2006). Choosing to take control in type 2 diabetes. Available at: www.diabetes.org.uk/Documents/ Reports/Choose-Control-report.pdf [Last accessed 16 July 2007]
24. Choe C, Edelman S. New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs. J Natl Med Assoc 2007;99:357-360 (Pubitemid 46608860)
25. Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Curr Med Res Opin 2007;23:905-917 (Pubitemid 46631494)
26. Farag A, Karam J, Nicasio J, et al. Prevention of type 2 diabetes: an update. Curr Diab Rep 2007;7:200-207 (Pubitemid 46957283)